Yuka Suganuma, Japan
The Jikei University Hospital Diabetology, Endocrinology and metabolismPresenter of 1 Presentation
IS THERE ANY CHANGE OVER TIME IN LINES OF THERAPY FOR SGLT2 INHIBITORS AMONG JAPANESE TYPE 2 DIABETES PATIENTS NEWLY PRESCRIBED THESE AGENTS?
Abstract
Background and Aims
This study was aimed at investigating changes over time in lines of therapy (LOT) for SGLT2 inhibitors (SGLT2i) among type 2 diabetes (T2D) patients newly prescribed these agents and their characteristics in Japan.
Methods
Data of T2D outpatients of our hospital since 1-1-2016 who received SGLT2i from the Standardized Structured Medical record Information eXchange 2 (SS-MIX2) was used. Among 620 patients, 369 patients were selected except those treated with polypharmacy including SGLT2i at referral and type 1 diabetes. Data included patient age at initial prescription of SGLT2i, duration of disease, body mass index (BMI), HbA1c value, history of cardiovascular (CV) events, and LOT for which SGLT2i had been prescribed. We used the Mann-Whitney test to compare before and after 1-1-2017.
Results
The patient’s characteristics [median (25-75%)] were following: age, 59.0 (49.0-68.0) years old; duration of disease, 6.0 (3.0-10.0) years; BMI, 27.1 (24.3-30.8) kg/m2; HbA1c, 8.1 (7.5-9.1) %; and history of CV events, 88 (23.8)%. Again, LOT for SGLT2i had been used in 3rd (2nd to 4th). SGLT2i were newly prescribed for 123 patients before 12-31-2016 (33.3 )%. SGLT2i were significantly more frequently prescribed in patients with a history of CV events from 2017 onwards (P = 0.006) and in earlier LOT in 2017 than in 2016 (P = 0.001).
Conclusions
This study revealed that SGLT2i were more frequently prescribed in patients with a history of CV events and in earlier LOT after 1-1-2017 than before.